US11103846B2 - Method and system for manufacturing of biopharmaceutical products - Google Patents

Method and system for manufacturing of biopharmaceutical products Download PDF

Info

Publication number
US11103846B2
US11103846B2 US16/763,787 US201816763787A US11103846B2 US 11103846 B2 US11103846 B2 US 11103846B2 US 201816763787 A US201816763787 A US 201816763787A US 11103846 B2 US11103846 B2 US 11103846B2
Authority
US
United States
Prior art keywords
product
inlet
suite
suites
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/763,787
Other languages
English (en)
Other versions
US20200384433A1 (en
Inventor
Johan Rosenquist
Daria Donati
Mia Margareta Elisabet Bennemo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytiva Sweden AB
Original Assignee
Cytiva Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytiva Sweden AB filed Critical Cytiva Sweden AB
Assigned to GE HEALTHCARE BIO-SCIENCES AB reassignment GE HEALTHCARE BIO-SCIENCES AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DONATI, Daria, BENNEMO, Mia, ROSENQUIST, JOHAN
Assigned to CYTIVA SWEDEN AB reassignment CYTIVA SWEDEN AB CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GE HEALTHCARE BIO-SCIENCES AB
Publication of US20200384433A1 publication Critical patent/US20200384433A1/en
Application granted granted Critical
Publication of US11103846B2 publication Critical patent/US11103846B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0006—Controlling or regulating processes
    • B01J19/004—Multifunctional apparatus for automatic manufacturing of various chemical products
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/24—Stationary reactors without moving elements inside
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0093—Microreactors, e.g. miniaturised or microfabricated reactors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/24—Stationary reactors without moving elements inside
    • B01J19/245—Stationary reactors without moving elements inside placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J4/00—Feed or outlet devices; Feed or outlet control devices
    • B01J4/008—Feed or outlet control devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00002—Chemical plants
    • B01J2219/00004—Scale aspects
    • B01J2219/00011—Laboratory-scale plants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00002—Chemical plants
    • B01J2219/00004—Scale aspects
    • B01J2219/00011—Laboratory-scale plants
    • B01J2219/00013—Miniplants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00002—Chemical plants
    • B01J2219/00018—Construction aspects
    • B01J2219/0002—Plants assembled from modules joined together
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00781—Aspects relating to microreactors
    • B01J2219/00801—Means to assemble
    • B01J2219/0081—Plurality of modules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00781—Aspects relating to microreactors
    • B01J2219/00801—Means to assemble
    • B01J2219/0081—Plurality of modules
    • B01J2219/00813—Fluidic connections
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00781—Aspects relating to microreactors
    • B01J2219/00851—Additional features
    • B01J2219/00867—Microreactors placed in series, on the same or on different supports

Definitions

  • the present disclosure relates to a volume tailorable manufacturing system and a method for quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • Biopharmaceutical production puts high demand on biosafety to prevent loss of prevention of biological integrity, e.g., through release of harmful chemicals and/or organisms into the environment.
  • Biosafety is a term used to describe prevention mechanisms and measures required for the handling of biohazardous substances, such as biopharmaceutical compounds. Biosafety is used to protect from harmful incidents. Many laboratories handling biohazards employ an ongoing risk management assessment and enforcement process for biosafety following as categorized by a biosafety level referring to biocontainment precautions for laboratory work with infectious materials. Thus, a biosafety level is a set of biocontainment precautions required to isolate dangerous biological agents in an enclosed laboratory facility. The levels of containment range from the lowest biosafety level 0 (BSL-0) to the highest at level 4 (BSL-4).
  • precautions may consist of regular hand-washing and minimal protective equipment.
  • precautions may include airflow systems, multiple containment rooms, sealed containers, positive pressure personnel suits, established protocols for all procedures, extensive personnel training, and high levels of security to control access to the facility. Consequently, the higher the biosafety level, the higher the production cost and the higher the cost for providing production facilities capable of enabling such production.
  • An object of the present disclosure is to provide solutions which seek to mitigate, alleviate, or eliminate one or more of the above-identified deficiencies in the art and to provide solutions for flexible and cost-effective manufacturing of biopharmaceutical products, and more specifically to a volume tailorable manufacturing system for manufacturing according to a predetermined biosafety level classification.
  • this object is achieved by a volume tailorable manufacturing system for quality assured manufacturing of biosafety level classified biopharmaceutical products, the volume tailorable manufacturing system comprising one or more multi-product suites and a control facility configured to control a unidirectional flow in a circulation system of the one or more multi-product suites.
  • the circulation system is configured to interconnect the one or more multi-product suites and comprises separated supply and return systems.
  • the supply system comprising at least one inlet
  • the return system comprising at least one outlet that is paired with the inlet and provided at a spatially predetermined position from the inlet, and each inlet/outlet pair comprises a seal when not connected to an adjacent multi-product suite.
  • the volume tailorable manufacturing system provides the advantage of allowing an unprecedented flexibility in scale; both with regard to production volume flexibility and with regard to time to production inauguration.
  • each inlet/outlet pair is prepared for connection to a further inlet/outlet pair of a further multi-product suite and the seal of an inlet/outlet pair is configured to be broken to expand the volume tailorable manufacturing system with the further multi-product suite.
  • each inlet/outlet pair is prepared for connection to a further inlet/outlet pair of a further multi-product suite and an inlet/outlet pair is configured to be sealed when the connection to the further inlet/outlet pair is discontinued. Accordingly, the disclosed volume tailorable manufacturing system allows for easy production expansion or production limitation by adding or removing a further multi-product suite.
  • first and second multi-product suites are comprised in the volume tailorable manufacturing system, an inlet/outlet pair of the first multiproduct suite is connected to an inlet/outlet pair of the second multiproduct suite, and the control facility is configured to control a unidirectional flow in a circulation system interconnecting the first and second multi-product suites.
  • the supply system is configured as a central spine within a centre portion of the volume tailorable manufacturing system and is at least partly enclosed by the one or more multi-product suites.
  • the return system of each multi-product suite is configured as a passage along a perimeter of the volume tailorable manufacturing system.
  • each multi-product suite comprises a first communication interface to the supply system and a second communication interface to the return system.
  • the biosafety level classification is BioSafetyLevel 2, BSL2.
  • each multi-product suite is inter-operationally discrete from the other multi-product suites.
  • the one or more multi-product suites are micro modules configured for biopharmaceutical manufacturing, and wherein the separated supply and return systems are connected to a macrostructure comprising a hydration facility and warehouse facility.
  • the above mentioned object is also achieved by a method for expanding a production volume capability of a manufacturing system for quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • the manufacturing system comprises a first multi-product suite and a control facility configured to control a unidirectional flow in a circulation system of the first multi-product suites.
  • the circulation system comprises separated supply and return systems.
  • the supply system comprises an inlet
  • the return system comprises an outlet that is paired with the inlet and provided at a spatially predetermined position from the inlet
  • the inlet/outlet pair comprises a seal.
  • the method comprises a step of arranging a second multi-product suite in a position adjacent to the first multi-product suite so that a spatially predetermined position of an inlet/outlet pair of the second multi-product suite is arranged to mirror the spatially predetermined position of an inlet/outlet pair of the first multi-product suite.
  • the method further comprises a step of interconnecting the inlet/outlet pair of the first multi-product suite with the inlet/outlet pair of the second multi-product suite and breaking the seal of each inlet/outlet pair.
  • the biosafety level classification is BioSafetyLevel 2, BSL2.
  • the interconnecting comprises validating that a connection formed between the inlet/outlet pair of the first multi-product suite and the inlet/outlet pair of the second multi-product suite complies with requirements for quality assured manufacturing of BioSafetyLevel 2, BSL2, classified biopharmaceutical products and breaking the seal following such validation.
  • the quality assured manufacturing of the biopharmaceutical products associated with a biosafety level classification has been validated for each of the first and second multi-product suites and includes validation of respective inlet/outlet pairs, wherein validation of the second multi-product suite is uncorrelated to validation of the first multi-product suite and wherein the validation of respective inlet/outlet pairs comprises pre-validating a connection to be formed.
  • the above mentioned object is also achieved by a method for decreasing production volume capability of a manufacturing system for quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • the manufacturing system comprises at least two multi-product suites and a control facility configured to control a unidirectional flow in a circulation system of the one or more multi-product suites.
  • the circulation system is configured to interconnect the one or more multi-product suites and comprises separated supply and return systems.
  • Each multi-product suite comprises at least one inlet to the supply system and at least one outlet from the return system, wherein the outlet is paired with the inlet and provided at a spatially predetermined position from the inlet.
  • the two multi-product suites are arranged in adjacent positions having an inlet/outlet pair of the first multi-product suite interconnected with an inlet/outlet pair of the second multi-product suite.
  • the method comprises to disconnect the first and second multi-product suites by sealing the inlet/outlet pair of the first multi-product suite and/or the second multi-product suite and adapting the control facility to control a unidirectional flow in a circulation system of the first multi-product suite.
  • FIG. 1 illustrates an example schematic arrangement of a volume tailorable manufacturing system of the present disclosure
  • FIG. 3 is a flowchart illustrating example method steps according to some embodiments.
  • FIG. 4 is a flowchart illustrating example method steps according to some embodiments.
  • FIG. 5 discloses an example configuration of a multi-product suite and flows for manufacturing of biohazardous compounds
  • FIG. 6 shows a schematic diagram of an example control facility.
  • FIG. 1 illustrates an example configuration of a volume tailorable manufacturing system that may be used in conjunction with various embodiments of the present invention for volume tailorable quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • the volume tailorable manufacturing system 100 disclosed in FIG. 1 comprises a first multi-product suite 110 , e.g., for manufacturing of a 1 st compound, and optional 2 nd and 3 rd multi-product suites 111 , 112 , wherein the 2 nd multi-product suite 111 may be introduced to enable a scale increase of the production of compound A.
  • the 3 rd multi-product suite 112 is disclosed as enabling a more varied production at within the manufacturing system, e.g., by producing compound B in the expanded production facility.
  • the 3 rd multi-product suite 112 may of course also be used for compound A, should there be a need for significantly increasing the production of this compound.
  • the 1 st and 2 nd multi-product suites 110 , 111 are indicated as being dedicated to production of compound A, they may in fact be used for production of multiple compounds and the 1 st and 2 nd multi-product suite 110 , 111 may comprise a number of biopharma production environments that are separated from one another, but joined to a unidirectional circulation system of the multi-product suites.
  • a control facility, arranged within one or more of the multi-product suites, is configured to control a unidirectional flow in the circulation system of the one or more multi-product suites.
  • the circulation system is configured to interconnect the one or more multi-product suites as well as providing a circulation system within each multi-product suite.
  • the circulation system comprises separated supply and return systems, the supply system comprising at least one inlet, the return system comprising at least one outlet that is paired with the inlet and provided at a spatially predetermined position from the inlet, and each inlet/outlet pair comprises a seal when not connected to an adjacent multi-product suite.
  • the inlet and outlet are arranged on the same floor level of a building block.
  • FIG. 2 a illustrates an example embodiment of a volume tailorable manufacturing system architecture that may be used in conjunction with various embodiments of the present invention for volume tailorable quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • the volume tailorable manufacturing system 200 of the present disclosure comprises a first multi-product suite 210 and a control facility, e.g., a processor arranged within an area of the manufacturing system, within a separate control centre or as a cloud solution.
  • the control facility is configured to control a unidirectional flow in a circulation system of the multi-product suite 210 .
  • the circulation system is configured to interconnect the one or more multi-product suites.
  • the circulation system is also configured to allow circulation of personnel, raw material, products and waste as required for complying with the biosafety level classification of the production facility, i.e., the multi-product suite.
  • the biosafety level classification is BioSafetyLevel 2, BSL2 implying that the flow of personnel, raw, material, products and waste is a unidirectional flow.
  • BSL2 BiosafetyLevel 2
  • any type of biopharmaceutical production requiring BSL1 or BSL2 may be manufactured within the multi-product suites of the manufacturing facility.
  • biomolecules comprise mAbs, Rec proteins, vaccines, viral vectors, insulins, etc.
  • the circulation system comprises separated supply and return systems, the supply system 220 comprising at least one inlet 220 a , the return system 230 comprising at least one outlet 230 a that is paired with the inlet 220 a and provided at a spatially predetermined position from the inlet, e.g., having each inlet 220 a and outlet 230 a arranged with a predetermined respective width and arranged at a predetermined distance d from one another.
  • Each inlet/outlet pair 220 a / 230 a comprises a seal 240 when not connected to an adjacent multi-product suite, e.g., sealing the inlet 220 a with a first part of the seal 240 and sealing the outlet 230 a with a second part of the seal 240 , whereby the first and the second part of the seal 240 may be physically separated from one another.
  • the inlet and outlet are arranged on the same floor level of a building block.
  • the manufacturing system 200 further comprises clean room areas 260 , i.e., areas in which the biocontainment precautions stipulated by a given biosafety level classification must be complied with.
  • areas where such biocontainment precautions must be observed comprise a seed area, a USP area, a DSP area and lab areas.
  • the manufacturing system 200 also comprises preparatory areas 250 that provide key contributions to the biopharmaceutical manufacturing, but without the need for strict biocontainment precautions. Such areas comprise entrances, offices, storages, utility areas, support areas, media preparation areas and buffer preparation areas.
  • each inlet/outlet pair 220 a , 230 a is prepared for connection to a further inlet/outlet pair of a further multi-product suite and wherein the seal 240 of an inlet/outlet pair is configured to be broken to expand the volume tailorable manufacturing system with the further multi-product suite.
  • each inlet/outlet 220 a , 230 a pair is prepared for connection to a further inlet/outlet pair of a further multi-product suite and an inlet/outlet pair is configured to be sealed with a seal 240 when the connection to the further inlet/outlet pair is discontinued.
  • the disclosure of FIG. 2 a also depicts a seal 240 ′ at the end of the preparatory area 250 .
  • the interconnection of this area with a corresponding preparatory area of an adjacent multi-product suite does not require the safety level validation.
  • the ability to accomplish a quick connection also of these areas may provide user benefits; thus, the multi-product suites may be configured with a breakable seal also in this
  • FIG. 2 b illustrates an example embodiment of a manufacturing system architecture that may be used in conjunction with an embodiment whereby the manufacturing volume is tailored for increased production.
  • the production relates to quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • the 1 st and 2 nd multi-product suite has been connected so that that the volume tailorable manufacturing system 200 here comprises a first and a second multi-product suites 210 , 215 .
  • An inlet/outlet pair providing access to the separated supply and return system of the first multiproduct suite is connected to an inlet/outlet pair providing access to the separated supply and return system of the second multiproduct suite.
  • the control facility is configured to control a unidirectional flow in a circulation system formed by the supply and return system that interconnect the first and second multi-product suites. If the 1 st and 2 nd multi-product suite have been validated for the same biosafety level classification, e.g., BSL 2, validation of the connection area 225 , formed when connecting the two multi-product suites and breaking the seal will be possible with for the corresponding biosafety level classification in an expedited manner due to the pre-validation of the respective parts of the manufacturing system. Consequently, a main benefit of the present disclosure is the ability to offer scalable production, adapted for strict biocontainment precautions, which only require validation of a connecting structure prior to use.
  • biosafety level classification e.g., BSL 2
  • connection between inlet/outlet pairs of two adjacent multi-products suites is formed by matching the position of these inlet/outlet pairs.
  • the interconnection may be achieved by using intermediary connectors between the respective inlet/outlet pairs.
  • the supply system 220 is configured as a central spine within a centre portion of the volume tailorable manufacturing system and being at least partly enclosed by the one or more multi-product suites, e.g., enclosed by the clean room areas 260 .
  • the return system 230 of each multi-product suite may be configured as a passage along a perimeter of the volume tailorable manufacturing system and at least partly enclosing the clean room areas.
  • FIG. 2 c illustrates an example embodiment of a manufacturing system architecture that may be used in conjunction with various embodiments of the present invention for volume tailorable quality assured manufacturing of biopharmaceutical products associated with a biosafety level classification.
  • an expanded manufacturing system 200 has been achieved using multi-product suites 211 , 212 configured to be connected to further multi-products suites. Consequently, 2 nd and a 3 rd multi-product suites 211 , 212 each comprises two inlet/outlet pairs having respective outlets provided at spatially predetermined positions from corresponding inlets, and each inlet/outlet pair comprising a seal 240 when not connected to an adjacent multi-product suite.
  • each multi-product suite is inter-operationally discrete from the other multi-product suites, implying that a compound A may be manufactured in a first multi-product suite, while a compound B is manufactured in a second multi-product suite that share a circulation system with the first multi-product suite.
  • supply of fresh air may be supplied to the first and second multi-product suite from a common air handler unit, however, each suite will have its own air circulation system that is independent of that of other suites in order to fulfil the BSL 2 requirements. It is of course also possible to use independent air handler units for each multi-product suite. While this will represent a slight increase the cost of the infrastructure required for the manufacturing, an advantage of having separation also of such supply systems is the shorter disruption occurring during the phase of expanding the manufacturing system with one or more further multi-product suites.
  • the manufacturing system comprises one or more multi-product suites, e.g., as disclosed in FIGS. 2 a - c , and a control facility configured to control a unidirectional flow in a circulation system of the one or more multi-product suites.
  • the circulation system is configured to interconnect the one or more multi-product suites and comprises separated supply and return systems.
  • the supply system comprises an inlet
  • the return system comprises an outlet that is paired with the inlet and provided at a spatially predetermined position from the inlet
  • the inlet/outlet pair comprises a seal.
  • the method comprises arranging S 31 a second multi-product suite in a position adjacent to the first multi-product suite so that a spatially predetermined position of an inlet/outlet pair of the second multi-product suite is arranged to mirror the spatially predetermined position of an inlet/outlet pair of the first multi-product suite.
  • the inlet/outlet pair of the first multi-product suite is interconnected S 32 with the inlet/outlet pair of the second multi-product suite; and the seal of each inlet/outlet pair is broken S 34 .
  • the method comprises validating the 1 st multi-product suite for manufacturing according to biosafety level classification and/or validating the 2 nd multi-product suite for manufacturing according to biosafety level classification prior to installation of the multi-product suites, wherein the validating of the respective multi-product suits is performed independent of the validating of the other multi-product suite, i.e., representing a pre-validation process for the respective production facilities.
  • the quality assured manufacturing of the biopharmaceutical products associated with a biosafety level classification has been validated for each of the first and second multi-product suites and includes validation of respective inlet/outlet pairs, wherein validation of the second multi-product suite is uncorrelated to validation of the first multi-product suite and wherein the validation of respective inlet/outlet pairs comprises pre-validating a connection to be formed.
  • the validation is performed for biosafety level classification BioSafetyLevel 2, BSL2.
  • the interconnecting comprises validating S 33 that a connection formed between the inlet/outlet pair of the first multi-product suite and the inlet/outlet pair of the second multi-product suite complies with requirements for quality assured manufacturing of BioSafetyLevel 2, BSL2, classified biopharmaceutical products and breaking S 34 the seal only following such validation.
  • the manufacturing system comprises two more multi-product suites, e.g., as disclosed in FIG. 2 b or c , and a control facility configured to control a unidirectional flow in a circulation system of the one or more multi-product suites.
  • the circulation system is configured to interconnect the one or more multi-product suites and comprises separated supply and return systems.
  • Each multi-product suite comprises at least one inlet to the supply system and at least one outlet from the return system, wherein the outlet is paired with the inlet and provided at a spatially predetermined position from the inlet.
  • the two multi-product suites are arranged in adjacent positions having an inlet/outlet pair of the first multi-product suite interconnected with an inlet/outlet pair of the second multi-product suite.
  • the method comprises to disconnect S 41 the first and second multi-product suites by sealing the inlet/outlet pair of the first multi-product suite and/or the second multi-product suite and adapting S 42 the control facility to control a unidirectional flow in a circulation system of the first multi-product suite.
  • FIG. 5 details are schematically provided for the above discussed volume tailorable manufacturing system comprising a multi-product suite configured for BSL2.
  • areas subject to corresponding biosafety level requirements are indicated with corresponding patterns.
  • the arrows are used to disclose various flows of raw material, products and waste that may occur in the manufacturing system.
  • the manufacturing system comprises utilities areas 510 and entrance/office/storage areas 520 that are not subjected to specific biocontainment precaution requirements.
  • the manufacturing system also comprises an entry corridor 560 , support areas 570 , media preparation areas 580 and buffer preparation areas 590 that require some safety precautions but where these precautions do not fulfil the BSL2 requirements.
  • Areas where the specific requirements of BSL2 must be observed comprise an exit corridor 530 , i.e., a return system, and clean room facilities, i.e., a multiproduct suite 540 comprising a seed area, a USP area, a DSP area.
  • a multiproduct suite 540 comprising a seed area, a USP area, a DSP area.
  • FIG. 5 indicates that the seed area and USP area should be subjected to the BSL2 requirements, but embodiments where different safety requirements apply to different areas within the biosafety environment are also within the scope of the present disclosure.
  • There is a supply of personnel, raw material to the biosafety areas from the entry corridor 560 i.e., a supply system.
  • the raw material may be received in the supply system from a media preparation area 580 or a buffer preparation area 590 , as illustrated by the arrows in FIG. 5 .
  • the entry and exit corridors, i.e., the supply and return systems, are arranged at a distance d from one another.
  • a corresponding, mirrored production facility may be arranged adjacent to the multiproduct suite of FIG. 5 and connected to the multiproduct suite.
  • there may be different safety requirements associated with the supply and return system which may impact the requirements on the respective connections between two adjoining multiproduct suites.
  • each multi-product suite comprises a first communication interface to the supply system and a second communication interface to the return system.
  • the first communication interface may comprise a materials delivery interface, e.g., for delivery of raw material as illustrated in FIG. 5 .
  • the second communication interface may comprise a product delivery interface.
  • the materials delivery interface and the product delivery interface are provided by means of air locks.
  • the materials delivery comprise supply material delivered to a designated multi-product suite in single-use equipment, the supply material comprising customized culture media and/or buffer.
  • the multi-product suites are arranged to receive materials delivery of single-use product contact components.
  • each multi-product suite comprises at least one further communication interface, also called a personnel access interface, controlled by a control unit in the multi-product suite and wherein the at least one further communications interface is arranged to control access of personnel to/from the multi-product suite.
  • the one or more multi-product suites are micro modules configured for biopharmaceutical manufacturing, and wherein the separated supply and return systems are connected to a macrostructure comprising a hydration facility and warehouse facility.
  • FIG. 6 shows a schematic diagram of an example control facility 600 configured for controlling a unidirectional flow in a circulation system of the one or more multi-product suites.
  • the control facility comprises a memory 631 , processing circuitry 632 , and input device 633 .
  • the control facility may also comprise data interface providing data connectivity with the circulation system and the supply and return system comprised in the circulation system.
  • processing circuitry may refer to, for example, one or more computers, computing entities, distributed systems, processing devices, processing entities, and/or any combination of devices or entities adapted to perform the functions, operations, and/or processes described herein.
  • functions, operations, and/or processes may include, for example, transmitting, receiving, operating on, processing, storing, creating/generating, and/or similar terms used herein.
  • the control facility 600 is configured to execute a computer program product comprising at least one non-transitory computer readable storage medium having computer-executable program code instructions store therein.
  • control of the unidirectional flow in a circulation system of the one or more multi-product suites may be achieved, i.e., controlling the unidirectional flow whereby personnel, raw material and other types of supply material is provide to the multi-product suites by means of a supply system of the circulation system and evacuated from the multi-products suites by means of the return system of the circulation system.
  • the control facility is configured to ensure that there is no direct communication between the supply system and the return system.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • General Factory Administration (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Ventilation (AREA)
  • Saccharide Compounds (AREA)
US16/763,787 2017-11-16 2018-11-15 Method and system for manufacturing of biopharmaceutical products Active US11103846B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1718917 2017-11-16
GB1718917.6 2017-11-16
GBGB1718917.6A GB201718917D0 (en) 2017-11-16 2017-11-16 Method and system for manufacturing of biopharmaceutical products
PCT/EP2018/081416 WO2019096925A1 (fr) 2017-11-16 2018-11-15 Procédé et système de fabrication de produit biopharmaceutiques

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/081416 A-371-Of-International WO2019096925A1 (fr) 2017-11-16 2018-11-15 Procédé et système de fabrication de produit biopharmaceutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/381,588 Continuation US11648523B2 (en) 2017-11-16 2021-07-21 Method and system for manufacturing of biopharmaceutical products

Publications (2)

Publication Number Publication Date
US20200384433A1 US20200384433A1 (en) 2020-12-10
US11103846B2 true US11103846B2 (en) 2021-08-31

Family

ID=60805597

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/763,787 Active US11103846B2 (en) 2017-11-16 2018-11-15 Method and system for manufacturing of biopharmaceutical products
US17/381,588 Active US11648523B2 (en) 2017-11-16 2021-07-21 Method and system for manufacturing of biopharmaceutical products

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/381,588 Active US11648523B2 (en) 2017-11-16 2021-07-21 Method and system for manufacturing of biopharmaceutical products

Country Status (7)

Country Link
US (2) US11103846B2 (fr)
EP (1) EP3710154A1 (fr)
JP (2) JP2021503589A (fr)
KR (2) KR102618428B1 (fr)
CN (1) CN111315475B (fr)
GB (1) GB201718917D0 (fr)
WO (1) WO2019096925A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023325A1 (fr) * 2020-07-27 2022-02-03 Basf Se Unité de production de phosgène
WO2022023246A1 (fr) * 2020-07-27 2022-02-03 Basf Se Unité de production de phosgène
EP4208286A1 (fr) 2020-09-01 2023-07-12 CureVac RNA Printer GmbH Dispositif de fabrication d'un produit pharmaceutique
US20230201817A1 (en) * 2021-12-23 2023-06-29 Biontech Delivery Technologies Gmbh Modular drug production system

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832915A1 (de) 1988-09-28 1990-03-29 Martin Gabler Reinraum
EP0410098A2 (fr) * 1989-07-24 1991-01-30 KUFLER & HROSS GMBH & CO. KG Système d'espace en construction modulaire pour un climat spécial
CA1294169C (fr) 1987-05-21 1992-01-14 Lawrence E. Wetzel Module de type salle blanche
FR2819536A1 (fr) 2001-01-12 2002-07-19 Bernard Gaffet Laboratoire modulaire de niveau de confinement p2,p2+ ou p3
DE102004026338A1 (de) 2004-05-26 2005-12-15 Keller, Bernhard, Prof. Dr. Sicherheitslabor
WO2009002334A1 (fr) 2007-06-26 2008-12-31 Welch Allyn, Inc. Dispositif microfluidique avec scellement élastomère
WO2010075389A2 (fr) 2008-12-23 2010-07-01 Xoma Technology, Ltd. Système de fabrication flexible
WO2011022325A2 (fr) 2009-08-16 2011-02-24 G-Con, Llc Salle blanche mobile auto-contenue modulaire
US7985382B1 (en) 2006-05-31 2011-07-26 The United States Of America As Represented By The Secretary Of The Army Mobile all hazards receipt facility/analytical laboratory
US20120077429A1 (en) 2010-09-20 2012-03-29 Chris Wernimont Mobile, modular cleanroom facility
GB2491974A (en) 2011-06-15 2012-12-19 Marshall Specialist Vehicles Ltd A building module for a modular forensic laboratory.
WO2017192595A1 (fr) 2016-05-02 2017-11-09 Massachusetts Institute Of Technology Système de synthèse chimique à étapes multiples reconfigurable et composants et procédés associés
US20170321443A1 (en) * 2016-03-10 2017-11-09 Lonza Ltd Customizable facility

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129772A3 (fr) * 1999-03-03 2001-11-07 Symyx Technologies, Inc. Distribution de fluide pour les microsystèmes de traitement chimique
US7312440B2 (en) 2003-01-14 2007-12-25 Georgia Tech Research Corporation Integrated micro fuel processor and flow delivery infrastructure
US7014674B2 (en) * 2003-07-28 2006-03-21 Flow Sciences, Inc. Biological safety cabinet
CN1942840B (zh) * 2004-02-03 2012-08-22 艾克塞勒雷克斯公司 制造系统和方法
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
WO2007106579A2 (fr) * 2006-03-15 2007-09-20 Micronics, Inc. Dosages d'acides nucléiques intégrés
US7998708B2 (en) * 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
KR20100028526A (ko) 2007-02-05 2010-03-12 마이크로칩 바이오테크놀로지스, 인크. 마이크로유체 및 나노유체 장치, 시스템 및 응용
US9005544B2 (en) 2009-10-15 2015-04-14 The Regents Of The University Of California Digital microfluidic platform for radiochemistry
EP2500083A4 (fr) 2009-11-10 2014-08-13 Toray Industries Module de membranes à fibres creuses destiné à être utilisé dans la production d'une substance chimique, et procédé de production d'une substance chimique
JP6427269B2 (ja) * 2014-07-11 2018-11-21 ジー−コン マニュファクチャリング インク． クリーンルーム、隔離若しくは閉じ込めキュービクル、ポッド、又はモジュールにユーティリティを供給するモジュール式部分
WO2016065056A1 (fr) 2014-10-22 2016-04-28 The Regents Of The University Of California Imprimante à microgouttelettes haute définition
JP6402028B2 (ja) * 2014-12-25 2018-10-10 澁谷工業株式会社 無菌作業システムおよび無菌作業システムにおける物品搬入方法
JP7009378B2 (ja) * 2016-03-10 2022-02-10 ロンザ リミテッド カスタマイズ可能施設
WO2017192286A1 (fr) 2016-05-02 2017-11-09 Purdue Research Foundation Systèmes et procédés de production de produit chimique
CN107390750A (zh) 2017-06-22 2017-11-24 宁波高新区新元华科技咨询有限公司 一种用于化工生产的加热器
CN107356128A (zh) 2017-09-07 2017-11-17 深圳市蓝豆芽科技有限公司 一种应用于化工生产的分体组合式冷凝装置
CN107570047A (zh) 2017-10-27 2018-01-12 孙建军 一种化工生产用可充分混合的搅拌罐

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1294169C (fr) 1987-05-21 1992-01-14 Lawrence E. Wetzel Module de type salle blanche
DE3832915A1 (de) 1988-09-28 1990-03-29 Martin Gabler Reinraum
EP0410098A2 (fr) * 1989-07-24 1991-01-30 KUFLER & HROSS GMBH & CO. KG Système d'espace en construction modulaire pour un climat spécial
DE3924455A1 (de) 1989-07-24 1991-01-31 Kufler & Hross Gmbh & Co Kg Modulares sonderklima-raumsystem
FR2819536A1 (fr) 2001-01-12 2002-07-19 Bernard Gaffet Laboratoire modulaire de niveau de confinement p2,p2+ ou p3
DE102004026338A1 (de) 2004-05-26 2005-12-15 Keller, Bernhard, Prof. Dr. Sicherheitslabor
US7985382B1 (en) 2006-05-31 2011-07-26 The United States Of America As Represented By The Secretary Of The Army Mobile all hazards receipt facility/analytical laboratory
WO2009002334A1 (fr) 2007-06-26 2008-12-31 Welch Allyn, Inc. Dispositif microfluidique avec scellement élastomère
WO2010075389A2 (fr) 2008-12-23 2010-07-01 Xoma Technology, Ltd. Système de fabrication flexible
WO2011022325A2 (fr) 2009-08-16 2011-02-24 G-Con, Llc Salle blanche mobile auto-contenue modulaire
US20120077429A1 (en) 2010-09-20 2012-03-29 Chris Wernimont Mobile, modular cleanroom facility
GB2491974A (en) 2011-06-15 2012-12-19 Marshall Specialist Vehicles Ltd A building module for a modular forensic laboratory.
US20170321443A1 (en) * 2016-03-10 2017-11-09 Lonza Ltd Customizable facility
WO2017192595A1 (fr) 2016-05-02 2017-11-09 Massachusetts Institute Of Technology Système de synthèse chimique à étapes multiples reconfigurable et composants et procédés associés

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Great Britain Search Report for GB Application No. 1718917.6 dated May 16, 2018 (7 pages).
Machine Translation of EP-0410098 (Year: 1991). *
PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2018/081416 dated Feb. 1, 2019 (11 pages).

Also Published As

Publication number Publication date
US11648523B2 (en) 2023-05-16
JP2021503589A (ja) 2021-02-12
JP2024062982A (ja) 2024-05-10
US20220001350A1 (en) 2022-01-06
KR20200087203A (ko) 2020-07-20
KR20240005160A (ko) 2024-01-11
GB201718917D0 (en) 2018-01-03
CN111315475B (zh) 2022-09-06
US20200384433A1 (en) 2020-12-10
CN111315475A (zh) 2020-06-19
EP3710154A1 (fr) 2020-09-23
WO2019096925A1 (fr) 2019-05-23
KR102618428B1 (ko) 2023-12-28

Similar Documents

Publication Publication Date Title
US11648523B2 (en) Method and system for manufacturing of biopharmaceutical products
Prasser et al. Data integration for future medicine (DIFUTURE)
Banerjee et al. Soluto-inertial phenomena: Designing long-range, long-lasting, surface-specific interactions in suspensions
JP5746047B2 (ja) フレキシブル製造システムおよびフレキシブル製造システムの提供方法
Remy et al. From minimal signed circuits to the dynamics of Boolean regulatory networks
Sell et al. Building the global vaccine manufacturing capacity needed to respond to pandemics
Nsaif et al. DVP: A novel high-availability seamless redundancy (HSR) protocol traffic-reduction algorithm for a substation automation system network
Dinov et al. High-throughput neuroimaging-genetics computational infrastructure
CN108021827A (zh) 一种基于域机制构建安全系统的方法及系统
Spandonidis et al. A novel intelligent iot system for improving the safety and planning of air cargo operations
WO2016116507A1 (fr) Simulation de procédé dans une cellule une installation de traitement
US20210034028A1 (en) Manufacturing system for biopharmaceutical products
CN106971068A (zh) 一种生物医学实验室资源开放共享管理信息系统
Lau et al. A novel link failure detection and switching algorithm for dissimilar redundant UAV communication
Kwon et al. Measures to Ensure the Sustainability of Information Systems in the COVID-19 Environment
Owens Anthrax and smallpox errors highlight gaps in US biosafety
Buyel et al. Implementing small-scale models for biopharmaceutical development
Ferguson The Mission Critical Edge
Murrugarra Efficient Control Methods for Stochastic Boolean Networks
Finley et al. Point of View: The Front Lines of Biological Weapons Non-Proliferation
CN107277056A (zh) 一种基于大数据互联的电子白板驱动控制系统
Hroncich New directions in modular manufacturing: industry experts discuss recent trends in modular manufacturing
Pearson Designing & Implementing Pharmaceutical Clean Rooms
Hellander Scientific applications on GRID systems
SRINIVASAN AI EMPOWERING PHARMACEUTICALS: REVOLUTIONIZING THE FUTURE OF HEALTHCARE

Legal Events

Date Code Title Description
AS Assignment

Owner name: GE HEALTHCARE BIO-SCIENCES AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSENQUIST, JOHAN;DONATI, DARIA;BENNEMO, MIA;SIGNING DATES FROM 20171220 TO 20180115;REEL/FRAME:052651/0077

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: CYTIVA SWEDEN AB, SWEDEN

Free format text: CHANGE OF NAME;ASSIGNOR:GE HEALTHCARE BIO-SCIENCES AB;REEL/FRAME:054278/0311

Effective date: 20200612

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STCF Information on status: patent grant

Free format text: PATENTED CASE